source
- J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketJohnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The drugmakerEndpoints · 3mo ago↗ source
- Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer Review informed you about her…Endpoints · 3mo ago↗ source
- Two biotechs raise a combined $556M in latest spurt of IPOsSeaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.